最新ニュース SSR Mining (NASDAQ:SSRM) 株価情報

SSR Mining

SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half of Silver Standard's revenue is attributable to the production of gold, with a key portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Puna mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Puna mine.

SSR Mining Inc

Scotiabank initiates coverage on UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) with a Sector Outperform rating and announces Price Target of $23.

News

Price Target

Initiation

Analyst Ratings

URGN

Scotiabank Initiates Coverage On UroGen Pharma with Sector Outperform Rating, Announces Price Target of $23

HC Wainwright &amp; Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) with a Buy and maintains $4 price target.

Reiteration

VANI

HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target

Scotiabank initiates coverage on CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) with a Sector Perform rating and announces Price Target of $23.

CGON

Scotiabank Initiates Coverage On CG Oncology with Sector Perform Rating, Announces Price Target of $23

SOBO

South Bow Safely Restarted The Keystone Pipeline After Receiving Regulatory Approval From The Pipeline And Hazardous Materials Safety Administration, Following South Bow's Response To An Oil Release At Milepost 171 Of Keystone On April 8, 2025, Near Fort Ransom, North Dakota

BCTX

BriaCell Therapeutics Announces New Positive Survival Data In Its Phase 2 Study Of Bria-IMT Plus Check Point Inhibitors (CPI), Outperforming ADC Drugs In Hormone Receptor Positive (HR+) Metastatic Breast Cancer (MBC) Patients

President Donald Trump ordered a probe into tariffs on critical mineral imports, <a href="https://www.benzinga.com/markets/commodities" target="_blank" rel="noreferrer noopener">commodities</a> that are essential for the defense, energy, and technology sectors.
What happened? On Tuesday, Trump <a target="_blank" href="https://www.whitehouse.gov/presidential-actions/2025/04/ensuring-national-security-and-economic-resilience-through-section-232-actions-on-processed-critical-minerals-and-derivative-products/" rel="noreferrer noopener">signed an executive order</a> directing Commerce Secretary Howard Lutnick to conduct a national security review under Section 232 of the Trade Expansion Act—the same authority previously used to impose tariffs on steel and aluminum. Lutnick has 180 days to report back with findings, including recommendations on whether and how tariffs should be applied.
The probe will assess vulnerabilities in the supply chains of 50 minerals, including all the steps, from raw extraction to producing semi-finished goods like battery cathodes and wind turbines. The list will include rare earth elements and metals like cobalt, nickel, lithium, and uranium.
This order follows China's April 4 move to impose export controls on seven rare earth elements, which has effectively halted global shipments, as China currently supplies 30 of the 50 critical minerals listed by the U.S. Geological Survey.
Why It Matters? The U.S. reliance on imported critical minerals, particularly from geopolitical rivals like China, poses serious security and economic stability risks. These minerals are essential for advanced military systems, electric vehicles, renewable energy infrastructure, and consumer electronics.
Critical minerals experts Gracelin Baskaran and Meredith Schwartz from the Center for Strategic and International Studies warned about the lack of alternative supply chains.
"The restrictions apply to seven medium and heavy rare earths: samarium, gadolinium, terbium, dysprosium, lutetium, scandium, and yttrium. The United States is particularly vulnerable to these supply chains. Until 2023, China accounted for 99 percent of global heavy REEs processing," they <a target="_blank" href="https://www.csis.org/analysis/consequences-chinas-new-rare-earths-export-restrictions" rel="noreferrer noopener">said</a> in a discussion.
Baskaran and Schwartz noted that these minerals are foundational to advanced military systems, yet the U.S. has no capacity for heavy rare earth separation today.
Trump might find the solution on the seabed floor. His administration is reportedly drafting an executive order to fast-track seabed mining, and potato-sized nodules on the ocean floor contain vast amounts of cobalt, nickel, and rare earths.
"As the Trump administration has done with shipbuilding and critical minerals more broadly, catalyzing US government focus on the areas of greatest vulnerability to PRC (China) ambitions is essential," Alexander Gray, chief of staff to the U.S. national security adviser in the first Trump administration, <a target="_blank" href="https://www.ft.com/content/2205fc9a-67b5-4112-9b7f-cd89d011f5bb" rel="noreferrer noopener">said</a> for The Financial Times.
The U.S. has been absent from international negotiations on seabed mining as the International Seabed Authority's March conference ended without a go-ahead for mining in international waters, as environmentalists argued a poorly understood impact on the ecosystem.
Meanwhile, Vancouver-based The Metals Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) has confirmed that its subsidiary <a target="_blank" href="https://www.benzinga.com/government/regulations/25/03/44543787/tmc-pushes-for-the-fastest-pathway-to-commercial-production-despite-environmental-risks" rel="noreferrer noopener">initiated the permitting process</a> for exploring and mining international waters under a 1980 U.S. law. Still, debates persist about whether the U.S. can grant rights over something outside its jurisdiction.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44795047/exclusive-tariff-uncertainty-turns-traders-cautious-but-oil-silver-might-be-the-escape-hatch-says-market-analyst" target="_blank" rel="noreferrer noopener">Tariff Uncertainty Turns Traders Cautious — But Oil, Silver Might Be The Escape Hatch, Says Market Analyst</a></li>
</ul>
Image via Shutterstock

Government

Regulations

Commodities

Politics

Markets

Media

Trump Orders Critical Minerals Probe As China Tightens Controls Over Rare Commodities In Retaliatory Move

BLUE

Carlyle, SK Capital Partners, And Beacon Parent Holdings Announced That Beacon Merger Sub, Inc. Has Extended The Expiration Date Of Its Offer To Acquire All Of The Outstanding Common Stock Of Bluebird Bio, To Expire At One Minute After 11:59 P.M., New York City Time, On May 2, 2025

HC Wainwright &amp; Co. analyst Emily Bodnar maintains TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) with a Buy and lowers the price target from $20 to $10.

RNAZ

HC Wainwright & Co. Maintains Buy on TransCode Therapeutics, Lowers Price Target to $10

Scotiabank analyst Allan Verkhovski initiates coverage on Paylocity Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NASDAQ">PCTY</a>) with a Sector Perform rating and announces Price Target of $190.

PCTY

Scotiabank Initiates Coverage On Paylocity Holding with Sector Perform Rating, Announces Price Target of $190

Silvercorp Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SVM#AMEX">SVM</a>) reported quarterly sales of $75.10 million which beat the analyst consensus estimate of $58.30 million by 28.82 percent. This is a 75.96 percent increase over sales of $42.68 million the same period last year.

Earnings

Earnings Beats

Silvercorp Metals Q4 Sales $75.10M Beat $58.30M Estimate

WIIM

BriaCell Therapeutics shares are trading higher after the company announced new survival data from its Phase 2 study of Bria-IMT plus check point inhibitors.

JP Morgan analyst Bill Peterson downgrades United States Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) from Overweight to Neutral and lowers the price target from $43 to $38.

Downgrades

JP Morgan Downgrades United States Steel to Neutral, Lowers Price Target to $38

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) with a Buy and maintains $75 price target.

LEGN

HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $75 Price Target

Biotech

General

BriaCell Therapeutics Announces New Survival Data In Phase 2 Study Of Bria-IMT Plus Check Point Inhibitors; Says 'Median Overall Survival Of 17.3 Months Exceeds Historical Data Of 14.4 Months In TRODELVY, Says 'Survival data in triple negative breast cancer patients treated with the BriaCell regimen was comparable to TRODELVY'

LVTX

LAVA Therapeutics Announced That The Netherlands Enterprise Agency (Rijksdienst Voor Ondernemend Nederland, Rvo) Granted A Full Waiver Of The Final Payment Obligation Related To The Innovation Credit, In The Amount Of $5.1M

ABBOTT'S FINANCIAL GUIDANCE Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5%.
Abbott projects full-year 2025 adjusted operating margin to be 23.5% to 24.0% of sales.
Abbott projects full-year 2025 adjusted diluted earnings per share of $5.05 to $5.25 and second-quarter 2025 adjusted diluted earnings per share of $1.23 to $1.27.

Large Cap

Guidance

Health Care

Abbott Reaffirms 2025 Adjusted EPS Of $5.05-$5.25 And Consensus Of $5.15, With Organic Sales Growth Of 7.5%-8.5% And Adjusted Operating Margin Of 23.5%-24.0%

LYFT

Lyft Announced It Has Entered Into A Definitive Agreement To Acquire Freenow From BMW Group And Mercedes-benz Mobility For Approximately €175M Or $197M In Cash

Designed to assess the impact of CardiolRx&#x2122; on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.
Based on a successful end-of-Phase II meeting with the US FDA and subject to MAVERIC outcomes, Cardiol believes the results from MAVERIC will support a New Drug Application.
Data from Cardiol's Phase II MAvERIC-Pilot study presented at the American Heart Association Scientific Sessions 2024 showed that pericarditis patients treated with CardiolRx&#x2122; experienced marked and rapid reductions in pericarditis pain and inflammation, and a substantial reduction in the number of pericarditis recurrences per year.
Recurrent pericarditis is a debilitating heart condition that results in chest pain, shortness of breath and fatigue, physical limitations, reduced quality of life, and hospitalizations.
CardiolRx&#x2122;, which has been granted US FDA Orphan Drug Designation for this indication, is a small molecule oral drug targeting inflammasome pathway activation that is central to the development and progression of pericarditis.
Toronto, Ontario--(Newsfile Corp. - April 16, 2025) - Cardiol Therapeutics Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/CRDL#NASDAQ">CRDL</a>) (TSX:<a href="https://www.benzinga.com/stock/CRDL#TSX">CRDL</a>) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today that Northwestern University has enrolled the first patient in the pivotal Phase III MAVERIC trial ("MAVERIC") evaluating Cardiol's lead drug candidate CardiolRx&#x2122; for the prevention of recurrent pericarditis. This multi-center, randomized, double-blind, placebo-controlled trial is designed to definitively assess the impact of CardiolRx&#x2122; on preventing recurrent pericarditis in patients at high risk for disease relapse and to support regulatory approval.
MAVERIC is currently being initiated at pre-eminent cardiovascular clinical research sites throughout the United States under an Investigational New Drug application authorized by the United States Food and Drug Administration ("US FDA").&nbsp;
MAVERIC is a Phase III, multi-center, randomized, double-blind, placebo-controlled trial designed to enroll 110 patients with recurrent pericarditis at approximately 20 clinical sites across the United States, Canada, and Europe. Patients who have been treated with an interleukin-1 ("IL-1") blocker for at least 12 months and are scheduled to have this treatment discontinued, will be randomly assigned to receive either CardiolRx&#x2122; or placebo following cessation of the IL-1 blocker. Discontinuation of IL-1 blocker therapy is associated with a high risk for recurrence and has been reported to occur within 12 weeks in up to 75% of patients. The primary clinical objective of the trial will be to assess the impact of CardiolRx&#x2122; versus placebo on freedom from a new episode of recurrent pericarditis at 24 weeks. Other clinical endpoints include time to a new episode of pericarditis recurrence, and changes in patient-reported pericarditis chest pain score and changes to the inflammatory marker C-reactive protein.
MAVERIC, formerly referred to as MAVERIC-2, follows positive results from Cardiol's Phase II MAvERIC-Pilot study. Data from MAvERIC-Pilot were previously reported on November 18 at the American Heart Association Scientific Sessions 2024 and showed that patients experienced marked and rapid reductions in both pericarditis pain and inflammation that were maintained throughout the study. In addition, the results demonstrated a substantial reduction in pericarditis episodes per year. Treatment with CardiolRx&#x2122; was shown to be safe and well tolerated in a patient population who presented with a high degree of disease burden.

CRDL

Cardiol Therapeutics Enrolls First Patient In Pivotal Phase III MAVERIC Trial Evaluating CardiolRx For Prevention Of Recurrent Pericarditis

Abbott Expects Q2 2025 Adjusted EPS Of $1.23 to $1.27 Versus Consensus Of $1.25

Jefferies analyst Corey Tarlowe upgrades Grocery Outlet Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GO#NASDAQ">GO</a>) from Hold to Buy and raises the price target from $13 to $18.

Upgrades

Jefferies Upgrades Grocery Outlet Holding to Buy, Raises Price Target to $18

Press Releases

SSR Mining Announces the Acquisition of the Cripple Creek & Victor Gold Mine From Newmont

SSR Mining Celebrates 5 Million Ounces of Gold Production From Marigold

SSR Mining Announces Expert Findings on Cause of the Çöpler Incident

SSR Mining to Announce Fourth Quarter and Full-Year 2024 Consolidated Financial Results on February 18, 2025

SSR Mining Appoints Laura Mullen to Board of Directors

SSR Mining Reports Fourth Quarter and Full-Year 2024 Results

SSR Mining to Voluntarily Delist From ASX

SSR Mining Announces Closing of Cripple Creek & Victor Acquisition

SSR Mining Provides 2025 Operating Guidance

SSR Mining to Announce First Quarter 2025 Consolidated Financial Results on May 6, 2025

Comments

SSR Mining

ニュース

最新ニュース SSR Mining (NASDAQ:SSRM) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル